- Home
- NERV vs TXMD Comparison
NERV vs TXMD Comparison
Compare NERV & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- TXMD
- Stock Information
- Founded
- NERV 2007
- TXMD 2008
- Country
- NERV United States
- TXMD United States
- Employees
- NERV N/A
- TXMD N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- TXMD Health Care
- Exchange
- NERV Nasdaq
- TXMD Nasdaq
- Market Cap
- NERV 12.0M
- TXMD 12.7M
- IPO Year
- NERV 2014
- TXMD N/A
- Fundamental
- Price
- NERV $2.15
- TXMD $1.08
- Analyst Decision
- NERV Hold
- TXMD
- Analyst Count
- NERV 1
- TXMD 0
- Target Price
- NERV $5.00
- TXMD N/A
- AVG Volume (30 Days)
- NERV 12.9K
- TXMD 17.5K
- Earning Date
- NERV 11-04-2025
- TXMD 11-11-2025
- Dividend Yield
- NERV N/A
- TXMD N/A
- EPS Growth
- NERV N/A
- TXMD N/A
- EPS
- NERV 1.48
- TXMD N/A
- Revenue
- NERV N/A
- TXMD $2,559,000.00
- Revenue This Year
- NERV N/A
- TXMD $427.09
- Revenue Next Year
- NERV N/A
- TXMD N/A
- P/E Ratio
- NERV $1.46
- TXMD N/A
- Revenue Growth
- NERV N/A
- TXMD 156.93
- 52 Week Low
- NERV $1.15
- TXMD $0.70
- 52 Week High
- NERV $2.98
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- NERV 48.19
- TXMD 45.34
- Support Level
- NERV $2.06
- TXMD $1.06
- Resistance Level
- NERV $2.25
- TXMD $1.14
- Average True Range (ATR)
- NERV 0.11
- TXMD 0.05
- MACD
- NERV -0.03
- TXMD -0.00
- Stochastic Oscillator
- NERV 24.19
- TXMD 15.79
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.